HMR1726,
teriflunomide,
Teriflunomide,
163451-81-8,
Flucyamide,
Aubagio,
A77 1726,
108605-62-5,
HMR 1726,
HMR1726,
(Z)-2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide,
A 771726,
HMR-1726,
SU 20,
teriflunomida,
teriflunomidum,
A771726,
RS 61980,
A-771726,
UNII-1C058IKG3B,
CHEBI:68540,
A 77-1726,
2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide,
(Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidide,
1C058IKG3B,
N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide,
(2z)-2-Cyano-3-Hydroxy-N-[4-(Trifluoromethyl)phenyl]but-2-Enamide,
(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide,
A77-1726,
2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-,
(2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile,
2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-,
2-Cyano-3-OH-N-(4-trifluoromethylphenyl)croton amide,
Teriflunomide [INN],
2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-,
MFCD00910058,
2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide,
Active metabolite of leflunomide,
Teriflunomide [USAN:INN],
Teriflunamide,
2-cyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]-2-butenamide,
Malononitrilamide,
Aubagio (TN),
SU-0020,
Leflunomide Impurity B,
Teriflunomide (USAN),
AC1NUIOH,
RS-61980,
2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide,
AC1L1GYH,
A 1726,
AC1L9H6I,
SCHEMBL22661,
Teriflunomide(A-771726),
Teriflunomide, A77 1726,
GTPL6844,
UTNUDOFZCWSZMS-YFHOEESVSA-N,
1185240-22-5,
(Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide,
BDBM50018011,
s4169,
ZINC13512456,
AKOS015994773,
API0000341,
CS-1031,
DB08880,
LE-0275,
SB16822,
AC-26446,
AJ-63994,
CC-10329,
HY-15405,
LS-46899,
SC-90977,
RT-011141,
ST24036515,
SW219377-1,
Leflunomide-d4 Metabolite (Teriflunomide-d4),
D10172,
EN300-189832,
AB01565775_02,
A801897,
C-16971,
J-010046,
N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide,
N-[4-(Trifluoromethyl)phenyl]-2-cyano-3-hydroxycrotonamide,
(Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide,
2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile,
2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-,
(2E)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile,
(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide),
2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide (E/Z)-mixture,
Leflunomide Related Compound B, United States Pharmacopeia (USP) Reference Standard,
(2Z)-3-oxidanylidene-2-[oxidanyl-[[4-(trifluoromethyl)phenyl]amino]methylidene]butanenitrile,
N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-beuteamide, LEF-M,
Simvistatin,
CHEMBL973,
D05LAR,
D07QFP,
D08TRA,
D09PUR,
A77-1726 (monosodium salt),
C12H9F3N2O2,
CID3898,
Teriflunomide (unspecified stereo),
C12-H9-F3-N2-O2,
CID444960,
CID5479847,
CS-O-05920,
ANTIPROLIFERATIVE AGENT A771726,
B1850,
T3287,
C072876,
C527525,
2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)-crotoneamide,
(Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-3-enamide,
(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phe-nyl]-2-butenamide,
79902-63-9,
A26,